Laserna Mendieta, Emilio J.Úbeda Vargas. VictoriaAmorena, EdurneSavarino, Edoardo V.Casabona Francés, SergioColetta, MarinaMolina Infante, JavierPérez Martínez, IsabelRossi, Carlo MaríaHonrubia López, Raúl2026-07-102026-07-102026Laserna-Mendieta, E. J., Úbeda-Vargas, V., Amorena, E., Savarino, E. V., Casabona-Francés, S., Coletta, M., Molina-Infante, J., Pérez-Martínez, I., Rossi, C. M., Dilaghi, E., Guagnozzi, D., Blas-Jhon, L., Betoré, E., Fernández-Fernández, S., Naves, J. E., Roales, V., Piccirelli, S., Granja-Navacerrada, A., Honrubia-López, R., … Lucendo, A. J. (2026). Dupilumab for eosinophilic esophagitis in adolescents and adults: Real-world outcomes across different dosing regimens from the eoe connect registry. American Journal of Gastroenterology. https://doi.org/10.14309/ajg.00000000000040880002-92701572-0241https://hdl.handle.net/11268/17262Real-world data on dupilumab for eosinophilic esophagitis (EoE), particularly regarding flexible dosing and fibrostenotic phenotypes, are scarce. Objective: To evaluate the effectiveness and safety of dupilumab in clinical practice using the EoE CONNECT registry.engAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/MedicinaEsofagitis EosinofílicaEfectos Colaterales y Reacciones Adversas Relacionados con MedicamentosPráctica Clínica Basada en la Evidenciajournal article10.14309/ajg.0000000000004088open accessTratamiento médicoSistema digestivoEfectos químicosGoal 3: Ensure healthy lives and promote well-being for all at all ages